The pharmaceutical industry is preparing for an accelerated pace of consolidation, with the number of mergers up 39% since 2017. This year has already witnessed its first ‘super merger’ between two of the world’s largest pharmaceutical companies, Bristol-Myers Squibb (NYSE: BMY) and Celgene (Nasdaq: CELG) valued at $74 billion.
The key drivers behind the latest round of mergers and acquisitions activity stem from the pressure to cut costs and achieve greater economies of scale , according to World Wide Technology, a technology service provider, combined with the ever-increasing cost of drug development and the mounting pressure to innovate faster. Drugs typically take 12 years from the initial discovery stage until they are market ready, with the estimated cost of £1.15 billion ($1.50 billion) per drug, and only 1 in 5,000 medicines making it to the market.
As the prospect of cost savings excites the minds of business leaders operating in the sector, pharmaceutical companies are looking for new avenues to free up budget and deliver game-changing healthcare solutions faster, according to Dave Locke, EMEA chief technology officer at World Wide Technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze